These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30066936)

  • 1. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
    Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.
    Kitayama K; Kawamoto T; Kawakami Y; Hara H; Takemori T; Fujiwara S; Yahiro S; Miyamoto T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
    Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reoxygenation using a novel CO2 therapy decreases the metastatic potential of osteosarcoma cells.
    Harada R; Kawamoto T; Ueha T; Minoda M; Toda M; Onishi Y; Fukase N; Hara H; Sakai Y; Miwa M; Kuroda R; Kurosaka M; Akisue T
    Exp Cell Res; 2013 Aug; 319(13):1988-1997. PubMed ID: 23727023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
    Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
    J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcutaneous carbon dioxide induces mitochondrial apoptosis and suppresses metastasis of oral squamous cell carcinoma in vivo.
    Takeda D; Hasegawa T; Ueha T; Imai Y; Sakakibara A; Minoda M; Kawamoto T; Minamikawa T; Shibuya Y; Akisue T; Sakai Y; Kurosaka M; Komori T
    PLoS One; 2014; 9(7):e100530. PubMed ID: 24988190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
    Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
    Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
    [No Abstract]   [Full Text] [Related]  

  • 8. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
    Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
    Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
    Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcutaneous carbon dioxide suppresses epithelial-mesenchymal transition in oral squamous cell carcinoma.
    Iwata E; Hasegawa T; Takeda D; Ueha T; Kawamoto T; Akisue T; Sakai Y; Komori T
    Int J Oncol; 2016 Apr; 48(4):1493-8. PubMed ID: 26846904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles inhibits breast cancer-bone metastasis by targeting JAK-STAT signaling pathways.
    Ganesan K; Xu C; Xie C; Sui Y; Zheng C; Gao F; Chen J
    Chem Biol Interact; 2024 Jun; 396():111037. PubMed ID: 38719172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcutaneous application of CO2 enhances the antitumor effect of radiation therapy in human malignant fibrous histiocytoma.
    Onishi Y; Akisue T; Kawamoto T; Ueha T; Hara H; Toda M; Harada R; Minoda M; Morishita M; Sasaki R; Nishida K; Kuroda R; Kurosaka M
    Int J Oncol; 2014 Aug; 45(2):732-8. PubMed ID: 24889546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
    Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
    Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
    Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
    Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.